Bioventus Inc.

NASDAQ:BVS

Medical - Devices

Healthcare
$10.62 +2.11%

+$0.18 today

Market cap
$727.20M
Beta
0.67
P/E (TTM)
20.6
EPS (TTM)
$0.42
52W Low $5.81High $11.25

Volume 0.70M

Average 0.56M

BVS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Bioventus Inc.NASDAQ: BVS

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns positive

Q1 FY2026 net income was $3.95M, compared with -$3.32M a year earlier. Trailing-twelve-month net income was $33.69M.

Context

  • Net income amounted to 4.8% of revenue in FY2025, up 4.7 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of $53.08M (+94.6%) for the fiscal year ending Dec 2026, a slowdown from the +8676.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.95M-77.2% QoQ
Last fiscal yearDec 2025
$27.27M+8676.7% YoY
LTMMar 2026
$33.69M+201.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+218.8%+69.1%-149.7 pp
1 year+8676.7%+94.6%-8582.1 pp
3-year CAGR—+48.4%—
5-year CAGR+24.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
27.27M USD
Year-over-year change
+8676.7%
4-year CAGR
+24.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How BVS compares with its peers on the latest reported figures

  • BVS's LTM Mar 2026 net income of $33.69M is the 6th largest of the 9 companies compared; the peer median is $4.62M.
  • Its year-over-year change of +201.9% is the 2nd highest of 9, against a peer median of +38.1%.
  • Net income amounts to 5.8% of revenue for BVS, versus a peer median of 9.9%.
BVS Competitors Peer median
Net Income for BVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNNSmith & Nephew plcFY2025$625M +51.7%+41.0%10.1%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$495.8M +1612.2%—30.1%
OFIXOrthofix Medical Inc.LTM Mar 2026$178.05M +24.5%+67.1%21.6%
TELATELA Bio, Inc.LTM Jun 2026$41.18M +1.0%-4.3%51.5%
MDXGMiMedx Group, Inc.LTM Mar 2026$37.72M -5.6%—9.7%
BVSBioventus Inc.LTM Mar 2026$33.69M +201.9%—5.8%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$11.06M -80.5%-9.9%9.5%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$2.72M +117.1%+33.6%0.5%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$1.83M +115.2%—1.5%
Peer median (excluding BVS) $4.62M+38.1%+33.6%9.9%

Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income11.45M(144.65M)(121.2M)(318K)27.27M
Depreciation & Amortization34.88M55.4M57.37M49.56M47.01M
Deferred Income Tax(9.76M)(46.66M)(2.38M)(5.39M)(909K)
Stock-Based Compensation19.84M17.59M2.72M10.06M12.67M
Change in Working Capital(15.15M)(29.73M)(3.18M)(11.78M)(13.84M)
Accounts Receivables(20.05M)(17.67M)10.06M(10.67M)(916K)
Inventory3.18M(18.62M)(5.99M)(16.44M)8.57M
Accounts Payables0000(19.81M)
Other Working Capital1.72M6.56M(13.24M)15.32M(1.68M)
Other Non-Cash Items(18.28M)134.52M82.01M(3.33M)1.77M
Operating Cash Flow22.99M(13.54M)15.34M38.8M73.98M
Capital Expenditures(20.89M)(1.48M)(7.36M)(1.01M)(2.56M)
Acquisitions (Net)(262.87M)034.68M0(686K)
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(7.37M)(114.96M)(11.51M)23.97M0
Investing Cash Flow(283.76M)(116.44M)15.81M22.96M(3.25M)
Debt Repayment166.2M59.62M(23.26M)(59.58M)(42.91M)
Common Stock Issued109.41M5.82M778K2.44M2.07M
Common Stock Repurchased00000
Dividends Paid(367K)0000
Other Financing Activities(1.88M)(3.37M)(4.17M)2.56M(20.61M)
Financing Cash Flow273.37M62.08M(26.65M)(54.58M)(61.44M)
Effect of Forex Changes(228K)521K629K(2.56M)371K
Net Change in Cash12.37M(67.38M)5.13M4.62M9.66M
Free Cash Flow2.1M(15.02M)7.98M37.79M71.41M

Bioventus Inc.

NASDAQ:BVS

Intrinsic Alpha fair value

Locked

Current Price

$10.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.